Nasus Pharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSRX research report →
Range $22 – $22
Price Chart
About the company
Nasus Pharma Ltd. , a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
- CEO
- Brendan O'Grady
- IPO
- 2025
- Employees
- 7
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on NSRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $29.39M
- P/E
- -3.28
- Fwd P/E
- 12.64
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 3.44
- EV/EBITDA
- -3.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -158.83%
- ROIC
- -96.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-4,904,000
- Net Income
- $-5,856,000-282.2%
- EPS
- $-0.72-323.5%
- OCF Growth
- -639.5%
- FCF Growth
- -641.7%
- 52W High
- $9.50
- 52W Low
- $1.98
- 50D MA
- $3.43
- 200D MA
- $4.34
- Beta
- 4.20
- RSI (14)
- 41
- Avg Volume
- 17.60K
No earnings-call transcripts are available for NSRX yet.
- Free Float
- 33.1%
- Shares Outstanding
- 8.61M
- Float Shares
- 2.85M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | O'Grady Brendan P. | other | 0 |
| Jul 22, 26 | Teleman Dan Benjamin | other | 0 |
| Jun 17, 26 | Teleman Dan Benjamin | buy | 6,550 |
| Apr 22, 26 | Teleman Dan Benjamin | buy | 2,900 |
| Mar 31, 26 | Teleman Dan Benjamin | buy | 15,000 |
| Nov 20, 26 | Rubin Eyal | other | 40,549 |
| Mar 11, 26 | Silberman David | other | 10,000 |
| Mar 18, 26 | Teleman Dan Benjamin | other | 0 |
| Jan 7, 26 | Teleman Dan Benjamin | other | 318,856 |
| Mar 11, 26 | Shacham Sharon | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NSRX coverage
Recent articles, reports, and earnings notes.
No research on NSRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NSRX report →Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Nasus Pharma Announces Transition of Chief Financial Officer
globenewswire.com · Aug 19
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 17
Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why
defenseworld.net · Aug 5
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
globenewswire.com · Jul 28
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
globenewswire.com · Jul 28
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
globenewswire.com · Jun 22
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
globenewswire.com · Jun 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.